Ionis Pharmaceuticals Inc. (IONS)

63.05
NASDAQ : Health Technology
Prev Close 62.22
Day Low/High 62.39 / 65.25
52 Wk Low/High 48.27 / 86.58
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 140.66M
Market Cap 8.75B
EPS 2.10
P/E Ratio 19.34
Div & Yield N.A. (N.A)

Latest News

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Ionis Pharamaceuticals: Will Bullish Charts and Quant Upgrade Lead to Breakout?

Ionis Pharamaceuticals: Will Bullish Charts and Quant Upgrade Lead to Breakout?

Aggressive traders could go long here.

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Ionis Pharma downgraded at Goldman

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.

Bullish and Bearish Chart Reversals

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

Ionis upgraded at BMO

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Biogen and Ionis See Boost From Clinical Drug Trial

Biogen and Ionis See Boost From Clinical Drug Trial

Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.

Trending Tickers: MUR, DO, BIIB, VZ

Trending Tickers: MUR, DO, BIIB, VZ

As crude oil falls below $40, stocks tied to oil are reeling.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Lots of energy names facing the potential for lower prices.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher

Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher

Stocks break free of range-bound trading by late morning as gains in biotech help to offset losses in energy.

Ionis downgraded at BMO

Cramer: Avoid Sloppiness by Watching Your Stock Table Manners

The essence of sloppiness is to let it all ride, so look at your portfolio and decide what has moved too much and what you should take off.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.